South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
- Conditions
- Obesity
- Interventions
- Other: Life style intervention (dietician+ physiotherapist)Other: No interventionOther: Self management
- Registration Number
- NCT05176132
- Lead Sponsor
- Claus Bogh Juhl
- Brief Summary
People with BMI \>30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included. All participants with age 18 and 60 years.
To evaluate health status participants will be screened by for undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, polycystic ovary syndrome (PCOS), and joint pain and for quality of life at baseline, 1 year, and 5 years. Additionally, anthropometric measurements are collected and a biobank is established for future research studies.
People with obesity related disease will be offered participation in a 12 month personalized lifestyle intervention program aimed at improvement of health and self-perception.
The collected data will be used to detect the prevalence for obesity-related disease to identify predictors for future obesity related disease and to evaluate the effect of a lifestyle intervention on health and quality of life.
- Detailed Description
Obesity is associated with a variety of adverse health problems, and there is currently no effective scalable treatment with a durable effect. Additionally, well-known obesity related health problems are often underdiagnosed.
A Danish cohort of people with BMI \>30 kg/m2 is established on University Hospital South West Jutland. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included. Age range is defined as 18 and 60 years.
To evaluate health status all participants are screened by for undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, polycystic ovary syndrome (PCOS) and joint pain.
Data will be collected from questionnaires (Impact of Weight related on Quality of Life, Attitude to physical activity questionnaire, Adult Eating Behavior questionnaire, Berlin sleep apnea and Epworths Sleepiness scale, PCOS related questionnaire including Ferriman-Gallwey score, Work Ability Index, and weight history); clinical laboratory variables (HbA1c, glucose, c-peptide, lipid status, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), hemoglobin, thrombocytes, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), bilirubin, gamma glutamic transferase, lactate dehydrogenase (LDH), alkaline phosphatase, and creatinine levels); and anthropometric measurements (blood pressure, EKG, liver elastography, spirometry (forced expiratory volume during first second as a fraction of forced vital capacity (FEV1/FVC), hand grip strength, gait speed, and CT scan for estimation of the subcutaneous and visceral fat volume). People with diseases uncovered by the screening program will be referred to specialized departments or general practice for further assessment and treatment.
A biobank (blood, feces, urine) is established for future research studies. Patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dietitians and physiotherapists focusing on health improvement through personal motivation, perceived limitations and body accept. Additionally, participants are invited to a 1 year follow-up. All participants, independent of disease status, will be invited for at new screening 5 years after the initial visit.
The data collected for the cohort will be used to estimate the prevalence and development of new obesity-related diseases, and to identify predictors for obesity-related diseases. Finally, the effect of the lifestyle intervention-program will be evaluated.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2700
- BMI >30 (Obese cohort), BMI 20-25 (control group I), BMI 25-30 (control group II)
- Age 18-60 years
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description OBESE (BMI>30) Self management BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year. OBESE (BMI>30) Life style intervention (dietician+ physiotherapist) BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year. CONTROL Normal weight (BMI 20-25) No intervention 100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age CONTROL Overweight (BMI 25-30) No intervention 100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
- Primary Outcome Measures
Name Time Method Prevalence of unrecognized obesity-related diseases 5 years Undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, and polycystic ovary syndrome (PCOS).
- Secondary Outcome Measures
Name Time Method Gait-speed 5 years Gait Speed in 6 meters: High more than 1.1 m/s, Median 0.7-1.1 m/s, Low \<0.7 m/s
Body weight 5 years Participants are weighed in light clothes with no shoes or pocket items, lower is better
HbA1c 5 years HbA1c equal to or higher than 48 mmol/mol indicates diabetes
Epworth Sleepiness Scale 5 years Epworth Sleepiness Scale: Score 0-24. 0-5 Lower Normal Daytime Sleepiness, 6-10 Higher Normal Daytime Sleepiness, 11-12 Mild Excessive Daytime Sleepiness 13-15 Moderate Excessive Daytime Sleepiness, 16-24 Severe Excessive Daytime Sleepiness
Elastography 5 years Quantifies liver-stiffness as a measure of non-alcoholic fatty liver disease, lower is better
Berlin sleep apnea questionnaire 5 years Berlin sleep apnea questionnaire: The Berlin Questionnaire consists of three categories designed to elicit information regarding snoring (category 1), daytime somnolence (category 2), and the presence of obesity and/or hypertension (category 3). Categories 1 and 2 are considered positive if 2 or more responses are positive category 3 is considered positive if 1 response is positive and/or the body mass index is greater than 30 kg per meter squared. A patient is considered to have a high likelihood of sleep disordered breathing if 2 or more categories are positive.
EKG 5 years Under resting conditions, standard 12 lead electrocardiography
BMI 5 years Body weight / m2, lower is better
Adult Eating Behavior Questionnaire 5 years Measures eating behavior and appetite traits, descriptive
Fat-free mass 5 years Fat-free mass as estimated by bioimpedance measure, higher is better, no cut-of value
Prediabetes 5 years Hba1c 43-47 indicates prediabetes
Apnea hypopnoea index (AHI) 5 years Quantifies sleep apnea cardiorespiratory monitoring: AHI \< 5 per hour=normal or minimal, AHI ≥ 5, but \< 15 per hour: mild, AHI ≥ 15, but \< 30 per hour moderate and AHI ≥ 30 per hour: severe
Ferriman-Gallwey score self-reported 5 years Measures hirsutism and indicates risk of Polycystic ovary syndrome (PCOS): Whole body equal or less than 10: normal, over 10: increased, Face: more than 2 is considered high and indicates hirsutism
Hand-grip force five years Handgrip force: Higher is better, no defined cut-off value
Waist circumference 5 years Lower is better
Work-ability Index 5 years Measures the ability of a person to work, higher values are better, no cut-of value
SDOI attitude to physical activity questionnaire 5 years Measures a persons attitude to physical activity, higher is better, no cut-of value
Consultation systolic and diastolic blood pressure 5 years Standard cut-of values
24 hour blood pressure 5 years Measures mean blood pressure, day and night
Low density lipoprotein 5 years Dyslipidemia is defined as low density lipoprotein (LDL) \> 3 mmol/l or high density lipoprotein (HDL) cholesterol \< 1 mmol/l.
FEV1/FVC 5 years Indication of Chronic obstructive pulmonary disease as measured by spirometry
Impact of weight on quality of life-lite 5 years Measures weight associated quality of life, higher values are better, no cut-of value
Trial Locations
- Locations (1)
Hospital of South West Jutland, University hospital of Southern Denmark
🇩🇰Esbjerg, Denmark